Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Zolpidem extended-release in the long-term treatment of insomnia

Nature Clinical Practice Neurology volume 4, pages 358–359 (2008)Cite this article

boxed-textKrystal AD et al. (2008) Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep 31: 79–90

Zolpidem extended-release for the treatment of chronic primary insomnia remains effective and well tolerated when taken on an as-needed basis several nights per week for at least 6 months

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ancoli-Israel S and Roth T (1999) Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. Sleep 22 (Suppl 2): S347–S353

    PubMed  Google Scholar 

  2. Neubauer DN (2007) The evolution and development of insomnia pharmacotherapies. J Clin Sleep Med 3 (Suppl 5): S11–S15

    PubMed  PubMed Central  Google Scholar 

  3. Greenblatt DJ et al. (2006) Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. J Clin Pharmacol 46: 1469–1480

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Lisa Richards, Editorial Assistant, Nature Clinical Practice.

Author information

Author notes

  1. Johns Hopkins Bayview Medical Center, 4940 Eastern Avenue, Box 151, Baltimore, MD 21224, USA neubauer@jhmi.edu

Authors and Affiliations

  1. DN Neubauer is Associate Director of the Johns Hopkins Sleep Disorders Center and Medical Director of the Behavioral Sleep Medicine Program at the Johns Hopkins University School of Medicine, Baltimore, MD, USA.,

    David N Neubauer

Authors
  1. David N Neubauer
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author is a consultant for Neurocrine Biosciences, Pfizer, sanofi-aventis and Takeda Pharma, and has received speaker's honoraria from sanofi-aventis and Takeda Pharma.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neubauer, D. Zolpidem extended-release in the long-term treatment of insomnia. Nat Rev Neurol 4, 358–359 (2008). https://doi.org/10.1038/ncpneuro0821

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0821

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing